Usage médical du cannabis et des cannabinoïdes Questions et réponses à l’intention des décideurs politiques Observatoire européen des drogues et des toxicomanies (2019), Office des publications de l’Union européenne, Luxembourg Décembre 2018 PDF ISBN 978-92-9497-406-8 doi:10.2810/25727 TD-06-18-186-FR-N Table des matières : 5 Introduction 6 Quels sont les sujets abordés dans ce rapport? 7 Qu’entend-on par usage médical de cannabis et de cannabinoïdes? 11 PARTIE 1 Quelles données scientifiques attestent-elles d’un usage médical du cannabis et des cannabinoïdes? 11 Comment évaluer l’efficacité des médicaments? 12 Quels sont les données scientifiques récentes de l’efficacité du cannabis et des cannabinoïdes en tant que médicaments? 15 Quels sont les risques pour la santé associés à l’usage médical du [...]
Lire la suiteCannabis Use in Pregnancy. A Tale of 2 Concerns Michael Silverstein, MD, MPH1,2; Elizabeth A. Howell, MD, MPH3; Barry Zuckerman, MD1 JAMA. Published online June 18, 2019. doi:10.1001/jama.2019.8860 Original Investigation Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes Daniel J. Corsi, PhD; Laura Walsh, MSc; Deborah Weiss, PhD; Helen Hsu, MD; Darine El-Chaar, MD; Steven Hawken, PhD; Deshayne B. Fell, PhD; Mark Walker, MD Research Letter Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States Nora D. Volkow, MD; Beth Han, MD, PhD, MPH; Wilson M. Compton, MD, MPE; Elinore F. McCance-Katz, MD, PhD Full Text, https://jamanetwork.com/journals/jama/article-abstract/2736581 In an article in JAMA, Corsi and colleagues1 present the results of a retrospective cohort study of 661 617 women designed to assess associations between maternal cannabis use during pregnancy and adverse obstetrical and [...]
Lire la suiteCannabis thérapeutique : au seuil de l’expérimentation Interview du Pr Nicolas Authier, chef du service de pharmacologie médicale, CHU de Clermont-Ferrand, président du Comité scientifique spécialisé temporaire (CSST) sur le cannabis thérapeutique JIM.fr, 16 juin 2019 cliquer sur "regardez sur Vimeo" ou : https://www.jim.fr/medecin/videos/e-docs/cannabis_therapeutique_au_seuil_de_lexperimentation_178085/document_jim_tube.phtml Chapitres Quelle différence existe-t-il entre cannabis thérapeutique et cannabis récréatif ? - 00:05 Quelle est la situation actuelle du cannabis thérapeutique en France ? - 00:54 Où en sont les travaux du CSST que vous présidez ? - 03:10 Quelles seront les indications du cannabis thérapeutiques pendant l’expérimentation ? 05:16 Quel est l’intérêt du cannabis thérapeutique [...]
Lire la suiteLong-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up Rafael G. dos Santos, Rafael Faria Sanches, Flávia de Lima Osório, Jaime E.C. Hallak Archive of Clinical Psychiatry, 2018, 45, 1, 22-4 DOI: 10.1590/0101-60830000000149 Abstract Background : Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for [...]
Lire la suiteMedical Cannabis No Solution to the Opioid Crisis Batya Swift Yasgur, MA, LSW Medscape Medical News, June 11, 2019 https://www.medscape.com/viewarticle/914256?nlid=130206_2052&src=WNL_mdplsnews_190614_mscpedit_psyc&uac=292598PZ&spon=12&impID=1994987&faf=1 Contrary to previous research and popular assumptions, legalization of, and broader access to, medical cannabis has not reduced opioid overdose death rates. A study at Stanford University in California showed no protective effect of medical cannabis. In fact, states that legalized medical cannabis actually experienced a 22.7% increase in opioid overdose deaths. "There has been an idea touted by people and the cannabis industry and everyone invested in finding solutions to the opioid crisis that passing cannabis laws is one way to do that," lead author [...]
Lire la suiteThe Use of Cannabis for Headache Disorders Bryson C. Lochte, Alexandre Beletsky, Nebiyou K. Samuel, Igor Grant Cannabis and Cannabinoid Research, 2017, Vol. 2, No 1., 61-71 https://doi.org/10.1089/can.2016.0033 Abstract Headache disorders are common, debilitating, and, in many cases, inadequately managed by existing treatments. Although clinical trials of cannabis for neuropathic pain have shown promising results, there has been limited research on its use, specifically for headache disorders. This review considers historical prescription practices, summarizes the existing reports on the use of cannabis for headache, and examines the preclinical literature exploring the role of exogenous and endogenous cannabinoids to alter headache pathophysiology. Currently, there is not [...]
Lire la suiteÉtat des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle Christian Sueur Psychotropes, 2017/3 (Vol. 23), p. 125-163. DOI 10.3917/psyt.233.0125 https://www.cairn.info/revue-psychotropes-2017-3-page-125.htm Résumé : L’utilisation thérapeutique des substances psychédéliques a été concomitante de la découverte du LSD et de la Mescaline après la Seconde Guerre mondiale. Ces utilisations thérapeutiques concernaient, à l’origine, essentiellement « l’accompagnement » des psychothérapies (thérapies psycholytiques), le traitement des addictions (alcool, puis opiacés) et, du fait de leurs capacités anxiolytiques et antidépressives, la prise en charge des troubles psychologiques post-traumatiques, les dépressions résistantes, les pathologies obsessionnelles et psychosomatiques (douleurs, migraines…) et l’accompagnement des fins [...]
Lire la suiteMedicinal Use of Synthetic Cannabinoids—a Mini Review P. Muralidhar Reddy, Nancy Maurya & Bharath Kumar Velmurugan Current Pharmacology Reports, 2019 https://doi.org/10.1007/s40495-018-0165-y Abstract Purpose of Review : This review gives an overview of the medicinal uses of synthetic cannabinoids and other related aspects on the basis of recent as well as earlier studies that the authors considered relevant to the context and scope of the review. Recent Findings Synthetic cannabinoids are laboratory synthesized products eliciting effects way more than their natural counterparts. These compounds are more potent in generating intoxicating effects and are also difficult to be detected in conventional screening tests. Their clinical side effects are also more pronounced than [...]
Lire la suiteLong-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton & Maria Roberta Cilio CNS Drugs, 2018 DOI : 10.1007/s40263-018-0589-2 Abstract Background : Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most published studies have not extended beyond 12–16 weeks. Objective : The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods : Patients aged 1–17 years with refractory epilepsy were enrolled in an open-label [...]
Lire la suiteA Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. G. Morrison, J. Crockett, G. Blakey, K. Sommerville Clinical Pharmacology in Drug Development, 2019, PMID : 30791225, DOI : 10.1002/cpdd.665 Abstract GW Pharmaceuticals' formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valproate are commonly used antiepileptic drugs. This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial investigated the impact of cannabidiol on steady-state pharmacokinetics of clobazam (and N-desmethylclobazam), stiripentol, and valproate; [...]
Lire la suite